Replacement of unfractionated heparin by low-molecular-weight heparin for postorthopedic surgery antithrombotic prophylaxis lowers the overall risk of symptomatic thrombosis because of a lower frequency of heparin-induced thrombocytopenia
نویسندگان
چکیده
1. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:10541061. 2. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397. 3. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:11441148. 4. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790. 5. Cools J, Peeters P, Veet T, et al. Genomic organization of human JAK2 and mutation analysis of its JH2-domain in leukemia. Cytogenet Cell Genet. 1999; 85:260-266. 6. Reiter A, Walz C, Watmore A, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res. 2005;65:2662-2667. 7. Peeters P, Raynaud SD, Cools J, et al. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia. Blood. 1997;90:2535-2540. 8. Griesinger F, Podleschny M, Steffens R, et al. A novel BCR-JAK2 fusion gene is the result of a translocation (9;22)(p24;q11) in a case of CML [abstract]. Blood. 2000;96:352a. 9. Schwaller J, Frantsve J, Aster J, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of fatal myeloand lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 1998;17:5321-5333. 10. Curtin NJ, Campbell PJ, Green AR. The Philadelphia translocation and preexisting myeloproliferative disorders. Br J Haematol. 2005;128:734-736.
منابع مشابه
IgG-class anti-PF4/heparin antibodies and symptomatic DVT in orthopedic surgery patients receiving different anti-thromboembolic prophylaxis therapeutics
BACKGROUND Heparin-induced thrombocytopenia (HIT) is a thromboembolic complication that can occur with unfractionated heparin (UFH) or low molecular weight heparin (LMWH). Our objective was to determine and compare the incidence of IgG-class HIT antibodies in patients undergoing total hip arthroplasty (THA) or total knee arthroplasty (TKA) with different antithrombotic prophylaxis therapies and...
متن کاملThe severity of trauma determines the immune response to PF4/heparin and the frequency of heparin-induced thrombocytopenia.
Heparin can induce heparin-induced thrombocytopenia (HIT). The combined effect of type of surgery (major vs minor) and heparin on this prothrombotic immune reaction to platelet factor 4 (PF4)/heparin was analyzed. In a randomized, double-blind study, trauma patients receiving low-molecular-weight (LMWH) or unfractionated heparin (UFH) for thrombosis prophylaxis were assessed for PF4/heparin-ant...
متن کاملCurrent concepts review: heparin-induced thrombocytopenia.
Immune-type (Type II) heparin-induced thrombocytopenia (HIT) is a rare but potentially fatal complication that can result from the use of heparin or its derivatives employed to reduce the risk of venous thromboembolic disease (VTED) after surgery. As such, the onset of HIT creates a therapeutic paradox: VTED prophylaxis that induces systemic thrombosis. Orthopaedic patients often necessitate ch...
متن کاملHeparin induced thrombocytopenia
Abstract Background and Objectives Heparin is still a commonly used anticoagulant in prophylaxis and treatment of thromboembolic events. Heparin-induced thrombocytopenia (HIT) is a life-threating adverse drug reaction of heparin. The diagnosis of HIT is made based on two important criteria, firstly clinical evaluation and secondly laboratory testing. In this comprehensive review, the authors w...
متن کاملENOXAPARIN or FONDAPARINUX CHOOSE YOUR ANTITHROMBOTIC AGENT
For many years unfractionated heparin (UFH) was the only antithrombotic agent available in the United States. However, during the past decade new antithrombotic agents have become available. Th e fi rst of these agents were the low-molecular weight heparins (LMWHs) followed more recently by the direct anti-Xa inhibitors, of which only fondaparinux is available in the United States. Low-molecula...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2005